J Intern Med 2006,260(5):399–408.PubMedCrossRef this website 7. Christou L: The global burden of bacterial and viral zoonotic infections. Clin Microbiol Infect 2011,17(3):326–330.PubMedCrossRef 8. Cascio A, Bosilkovski M, Rodriguez-Morales AJ, Pappas G: The socio-ecology of zoonotic infections. Clin Microbiol Infect 2011,17(3):336–342.PubMedCrossRef 9. Grais RF, Strebel P, Mala P, Watson J, Nandy R, Gayer M: Measles vaccination in humanitarian emergencies: a review of recent practice. Confl
Health 2011,5(1):21.PubMedCrossRef 10. Arduino PG, Tozasertib cell line Porter SR: Oral and perioral herpes simplex virus type 1 (HSV-1) infection: review of its management. Oral diseases 2006,12(3):254–270.PubMedCrossRef 11. Soriano V, Vispo E, Poveda E, Labarga P, Martin-Carbonero L,
Fernandez-Montero JV, Barreiro P: Directly acting antivirals against hepatitis C virus. J Antimicrob Chemother 2011,66(8):1673–1686.PubMedCrossRef 12. Mitrasinovic PM: Advances in the structure-based design of the influenza A neuraminidase inhibitors. Curr Drug Targets 2010,11(3):315–326.PubMedCrossRef 13. Pawlotsky JM: Treatment failure and resistance with direct-acting antiviral drugs against hepatitis Bucladesine supplier C virus. Hepatology 2011,53(5):1742–1751.PubMedCrossRef 14. Ghosh RK, Ghosh SM, Chawla S: Recent advances in antiretroviral drugs. Expert Opin Pharmacother 2011,12(1):31–46.PubMedCrossRef 15. Bergman SJ, Ferguson MC, Santanello C: Interferons
as therapeutic agents for infectious diseases. Infect Dis Clin North Am 2011,25(4):819–834.PubMedCrossRef 16. Bekisz J, Schmeisser H, Hernandez J, Goldman ND, Zoon KC: Human interferons alpha, beta and omega. Growth Factors 2004,22(4):243–251.PubMedCrossRef 17. Sulkowski MS, Cooper C, Hunyady B, Jia J, Ogurtsov P, Peck-Radosavljevic M, Shiffman ML, Yurdaydin C, Dalgard O: Management of adverse effects of Peg-IFN and ribavirin therapy for hepatitis C. Nat Rev Gastroenterol Hepatol 2011,8(4):212–223.PubMedCrossRef 18. Gandhi NS, Mancera RL: The structure of glycosaminoglycans and their interactions with proteins. Chem Biol Drug Des 2008,72(6):455–482.PubMedCrossRef 19. Bishop JR, Schuksz M, Esko JD: Heparan sulphate proteoglycans fine-tune Histone demethylase mammalian physiology. Nature 2007,446(7139):1030–1037.PubMedCrossRef 20. Germi R, Crance JM, Garin D, Guimet J, Lortat-Jacob H, Ruigrok RW, Zarski JP, Drouet E: Cellular glycosaminoglycans and low density lipoprotein receptor are involved in hepatitis C virus adsorption. J Med Virol 2002,68(2):206–215.PubMedCrossRef 21. Barth H, Schafer C, Adah MI, Zhang F, Linhardt RJ, Toyoda H, Kinoshita-Toyoda A, Toida T, Van Kuppevelt TH, Depla E, et al.: Cellular binding of hepatitis C virus envelope glycoprotein E2 requires cell surface heparan sulfate. J Biol Chem 2003,278(42):41003–41012.PubMedCrossRef 22.